JPM vs NVCT · P/E 14, rev $57.35B vs $304.5M cap
JPMorgan Chase & Co (JPM) versus Nuvectis Pharma Inc (NVCT) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
NVCT does not have a complete income-statement cache yet.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. NVCT currently screens at market cap $304.5M.
Not investment advice. Open the JPM and NVCT stock pages for the full models.
Not investment advice.